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LETTERS TO THE EDITOR
Balancing validity, utility and public health considerations in disorders
due to addictive behaviours
The concept of “behavioural (non-chemical) addictions”
was introduced close to three decades ago, and a growing body
of literature has emerged more recently on this and related
constructs1,2. Simultaneously, some authors have noted that
the classiﬁcation of behavioural addictions requires further ef-
fort3,4. Here we provide an update on this area, emphasizing
recent work undertaken during the development of the ICD-
11, and addressing the question of whether it is useful to have
a separate section on disorders due to addictive behaviours in
this classiﬁcation.
Both the DSM and ICD systems have long avoided the term
“addiction” in favor of the construct of “substance depend-
ence”. However, the DSM-5 includes gambling disorder in its
chapter on substance-related and addictive disorders, and
provides criteria for Internet gaming disorder, considering it
an entity requiring further study, and highlighting its similar-
ities to substance use disorders5-7. In the draft ICD-11, the
World Health Organization has introduced the concept of
“disorders due to addictive behaviours” to include gambling
and gaming disorders2,8. These disorders are characterized by
impaired control over engagement in the addictive behaviour,
the behaviour occupying a central role in the person’s life, and
continued engagement in the behaviour despite adverse con-
sequences, with associated distress or signiﬁcant impairment
in personal, family, social, and other important areas of func-
tioning2,8.
An important focus during the development of DSM-5 was
on diagnostic validators. Certainly, there is some evidence for
overlap between substance use disorders and disorders due to
addictive behaviours, such as gambling disorder, on key valida-
tors including comorbidity, biological mechanisms, and treat-
ment response5-7. For gaming disorder, there is increasing in-
formation on clinical and neurobiological features. For a wide
range of other putative behavioural addictions, less evidence
exists. Further, several of these conditions may also demon-
strate overlap with impulse control disorders (in DSM-IV and
ICD-10), including comorbidity, biological mechanisms, and
treatment response9.
The groups working on ICD-11 recognize the importance of
validators of mental and behavioural disorders, given that a
classiﬁcation system with greater diagnostic validity may well
lead to improved treatment outcomes. At the same time,
ICD-11 workgroups have focused in particular on clinical util-
ity and public health considerations in their deliberations,
with an explicit focus on improving primary care in non-spe-
cialist settings, consistent with the ICD-11’s emphasis on glob-
al mental health. Fine-grained differentiations of disorders
and disorder subtypes, even if supported by empirical work
on diagnostic validity, are arguably not as useful in contexts
where non-specialists provide care. However, associated dis-
ability and impairment are key issues in this perspective, sup-
porting the inclusion of gambling and gaming disorders in
ICD-112,8.
There are multiple reasons why the recognition of disorders
due to addictive behaviours and their inclusion in the nosol-
ogy together with substance use disorders may contribute to
improving public health. Importantly, a public health frame-
work for prevention and management of substance use dis-
orders may well be applicable to gambling disorder, gaming
disorder, and perhaps some other disorders due to addictive
behaviours (although the draft ICD-11 suggests that it may be
premature to include in the classiﬁcation any other disorder
due to addictive behaviours outside of gambling and gaming
disorders).
A public health framework to considering disorders due to
addictive behaviours arguably has a number of speciﬁc advan-
tages. In particular, it places appropriate attention on: a) the
spectrum from leisure-related behaviour without any harms
to health through to behaviour associated with signiﬁcant im-
pairment; b) the need for high-quality surveys of prevalence
and costs of these behaviours and disorders, and c) the utility
of evidence-based policy-making to reduce harm.
Although some may be concerned about the medicalization
of ordinary living and lifestyle choices, such a framework overt-
ly recognizes that some behaviours with addictive potential are
not necessarily and may never become a clinical disorder, and
it emphasizes that prevention and reduction of health and so-
cial burden associated with disorders due to addictive behav-
iours may be achieved in meaningful ways by interventions
outside the health sector.
Several other criticisms of the constructs of behavioural dis-
orders or disorders due to addictive behaviours may be raised
for discussion. We have previously pointed out in this journal
that additional work is needed to make strong claims about
diagnostic validity9, and the draft ICD-11 currently also lists
gambling and gaming disorders in the section on “impulse
control disorders”. Relatedly, there is a reasonable concern
that the boundaries of this category may be inappropriately
extended beyond gambling and gaming disorder to include
many other types of human activity. Some of these arguments
overlap with those which emphasize the dangers of a reduc-
tionist medical model of substance use disorders.
While cognizant of the importance of these issues, our view
is that the potentially large burden of disease due to behav-
ioural addictions requires a proportionate response, and that
the optimal framework is a public health one.
Here we have outlined reasons why a public health frame-
work that is useful for substance use disorders may also be
usefully applied to gambling disorder, gaming disorder and,
potentially, other health conditions due to addictive behav-
World Psychiatry 17:3 - October 2018 363
iours. This argument provides support for including substance
use disorders, gambling disorder and gaming disorder in a sin-
gle section of the chapter on mental, behavioural or neurode-
velopmental disorders in ICD-11.
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Evidence of the clinical utility of a prolonged grief disorder diagnosis
A substantial body of research has shown that prolonged
grief disorder (PGD), characterized by persistent and severe
separation distress, constitutes a disorder distinct from be-
reavement-related major depressive disorder (MDD) and
post-traumatic stress disorder (PTSD)1. Reviewing the available
evidence, the work group covering the Disorders Speciﬁcally
Associated With Stress section in the ICD-11 decided to slate
PGD for inclusion as a new stress response syndrome2. Still,
mental health professionals and laypersons have expressed
concerns that diagnosing PGD represents a “medicalization”
of normal grief reactions3. Fears of the overdiagnosis of nor-
mal responses remain4-6.
As a new disorder, it is of paramount importance to deter-
mine whether PGD is a clinically useful diagnosis. According to
First7, a mental disorder or diagnostic system has clinical utili-
ty if it: a) helps communication, b) facilitates effective inter-
ventions, c) predicts management needs and outcomes, and d)
differentiates disorder from non-disorder and comorbid dis-
orders. Whereas a large body of evidence has demonstrated
the construct, predictive and incremental validity of PGD, clini-
cians’ perceptions of its clinical utility have yet to be tested ex-
perimentally.
To address this gap, our group recently completed a two-
phase National Institute of Mental Health (NIMH)-funded ran-
domized controlled trial in the US that evaluated the clinical
utility of PGD by examining the impact of providing informa-
tion about the diagnosis on clinicians’ ability to differentially
diagnose PGD in “virtual standardized patients” (VSPs). The
use of VSPs allowed us to standardize clinical presentations,
control inﬂuential confounding variables and patient charac-
teristics, and avoid burdening bereaved participants. Using
VSPs (rather than written vignettes or clinicians selecting their
own patients8, as has been done in prior studies) increased the
external validity of this investigation.
In Phase 1 of the study, video-recorded case vignettes for
the VSPs were developed with the input of seven bereavement
experts. They reﬂected cases of PGD, normative grief not meet-
ing criteria for PGD, MDD, and PTSD. Four blinded, expert
diagnosticians were asked to review the VSPs and evaluate the
cases to establish “gold” or “criterion” standard diagnoses.
There was full agreement on 12 of the cases, which were in-
cluded in Phase 2 of the study.
In Phase 2, clinicians (N=120 completers) were randomized
to receive written information about PGD (informed) or not
(not informed). Participants were asked about their back-
ground and experience working with the bereaved, and were
invited to provide a diagnosis and treatment recommenda-
tions for four VSPs depicting normative grief, PGD, MDD and/
or PTSD. Participants were also surveyed about PGD’s clinical
utility. Participants included psychiatrists (17%), psychologists
(27%), social workers (43%), and other licensed clinicians
(13%). They were 76% female and 66%White.
We found that clinicians provided with information about
PGD, compared to those not receiving such information, were
4.5 times more likely to diagnose PGD accurately. There were
no signiﬁcant group differences in the likelihood of clinicians
accurately diagnosing normative grief, MDD or PTSD, but
there were signiﬁcant between-group differences in treatment
recommendations for PGD cases. Clinical utility ratings of the
PGD diagnostic criteria were high, with the majority of clini-
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